AR-15512 vehicle ophthalmic solution

DRUG3 trials

Sponsors

Aerie Pharmaceuticals

Conditions

Dry Eye Disease

Phase 3

Study Evaluating the Safety and Efficacy of AR-15512

CompletedNCT05285644

Aerie PharmaceuticalsDry Eye Disease

Start: 2022-05-09End: 2023-07-24Updated: 2025-07-23

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

CompletedNCT05360966

Aerie PharmaceuticalsDry Eye Disease

Start: 2022-07-18End: 2023-10-17Updated: 2025-07-23

A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512

CompletedNCT05493111

Aerie PharmaceuticalsDry Eye Disease

Start: 2022-11-01End: 2024-02-28Updated: 2025-08-13

Related Papers

Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal COMET-2 and COMET-3 Studies.

2025-09-30